£9m NHS Savings With HeartFlow 'Virtual FFR' Gets NICE Nod
Executive Summary
UK's National Institute for Health and Care Excellence has recommended the HeartFlow FFRct Analysis for stable patients with a suspected myocardial infarction. NICE was won over by the potential £9m savings that the technology can bring to the National Health Services in the next five years.
You may also be interested in...
Philips, HeartFlow Cut FFR R&D, Commercial Deal
HeartFlow has signed another deal with one of the medical imaging giants to promote its HeartFlow FFRct Analysis technology for diagnosing coronary heart disease, this time with Dutch group Philips. The collaboration will further expand Philips' intravascular imaging offerings, a space in which it is focused on becoming a leader.
TCT 2015: Heartflow’s FFR CT Could Bring Costs Down By One-Third
HeartFlow’s FFR CT imaging system has demonstrated that it can pare off over 30% of the average cost of treating symptomatic patients at intermediate risk of coronary disease, while improving their quality of life. Experts who have reviewed the data from a cost and quality-of-life analysis of the PLATFORM trial caution, however, that this result will have to be confirmed in large randomized trials before FFR CT imaging supplants other types of noninvasive testing.
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.